Engflag

Coversum

Quick links to important sections

Coversum

There is no image.

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Coversum

What is Coversum?

Coversum is a medication belonging to a class of drugs known as angiotensin-converting enzyme (ACE) inhibitors. It contains the active ingredient perindopril, which is primarily used to manage blood pressure and support cardiovascular health.

Mechanism of Action

The medication works by interfering with the body's production of angiotensin II, a naturally occurring substance that causes blood vessels to tighten and narrow. By inhibiting the enzyme responsible for creating this substance, the medication helps blood vessels relax and widen. This process results in lower blood pressure and makes it easier for the heart to pump blood throughout the body.

Therapeutic Use

Coversum is commonly prescribed for several cardiovascular conditions:

  • Hypertension: It is used to treat high blood pressure, helping to maintain it at more stable levels.
  • Heart Failure: It can be used to manage symptomatic heart failure, where the heart is unable to pump blood with sufficient force.
  • Stable Coronary Artery Disease: It is often utilized to reduce the risk of cardiac events in patients with a history of heart disease or those who have had a heart attack.

Role in Long-term Management

As a long-term treatment, the goal of this medication is to protect the cardiovascular system from the effects of high pressure and strain. By maintaining vascular relaxation, it helps prevent the long-term damage to the heart, kidneys, and brain that can occur when blood pressure remains elevated over time.

Regulatory References

  1. NLM MeSH Descriptor Data for Perindopril
  2. Perindopril: MedlinePlus Drug Information

What side effects are possible with Coversum?

Possible Side Effects and Safety Information

The safety profile of Coversum (Perindopril), an ACE inhibitor, is defined by classifications and constraints established in regulatory documents. Adverse reactions are grouped by the affected physiological system and by incidence frequency, which allows for communication of both common and severe potential effects.

Frequency-Classified Adverse Reactions

Adverse effects listed as Common (occurring in 1% to 10% of patients) include cough, dizziness, headache, hypotension (low blood pressure), and gastrointestinal symptoms such as nausea and diarrhea. Uncommon reactions may include generalized swelling known as angioedema, which involves sudden swelling of the face, extremities, lips, or tongue. This reaction, though uncommon, is designated as a major safety concern.

Serious Safety Considerations

Official labeling documents emphasize that angioedema involving the glottis or larynx is a rare but potentially fatal adverse reaction. Furthermore, use during the second and third trimesters of pregnancy is contraindicated due to the risk of fetal injury or death. Severe drops in blood pressure (symptomatic hypotension) may rarely lead to acute renal failure or other complications, particularly in vulnerable patients. Elevated potassium levels (hyperkalemia) have also been documented as a serious, rare risk.

Population and Exposure-Related Notes

The incidence of angioedema has been reported to be higher in Black patients compared to non-Black patients receiving ACE inhibitors. Regarding exposure, effects such as dizziness and hypotension are typically noted as more likely following the initial dose or during dose escalation, while angioedema may occur at any time during therapy. Regulatory constraints require specific safety considerations, such as the contraindication with concurrent use of Sacubitril/Valsartan due to the increased risk of angioedema.

Overdose and Emergency Response

Overdose and When to Seek Help

Overexposure to Coversum (Perindopril) is defined in regulatory documents by the severe exaggeration of its effects on the circulatory system. The most common officially documented presentation of overdose is severe hypotension (excessively low blood pressure), often accompanied by clinical signs such as dizziness, fainting, and an abnormally slow heart rate (bradycardia).

Severe Outcomes and Risks

Profound, sustained hypotension may lead to serious secondary outcomes affecting the renal system, including acute renal failure or oliguria (diminished urine output). Patients with pre-existing ischemic heart disease or cerebrovascular disease are documented to have a heightened risk of events such as a myocardial infarction or stroke due to the excessive blood pressure drop. Death is listed as a rare outcome of massive overexposure.

Required Emergency Actions

If overdose is suspected or severe symptoms manifest, immediate medical attention must be sought. The regulator-mandated first action for managing severe hypotension is placing the patient immediately in a supine position (lying flat). Management is symptomatic and supportive, typically involving an intravenous infusion of physiological saline or other volume expanders. Official documents note that the active metabolite, Perindoprilat, can be dialysed as a procedural intervention for removal.

Therapeutic Uses of Coversum

What Coversum Treats: Main Uses and Benefits

Coversum (perindopril) is commonly used across conditions presenting with acute episodes where symptoms related to heightened physiological activity (such as high blood pressure) or symptoms linked to organ-specific functional stress (like those seen in heart failure) may be part of symptomatic management. As a prescription medicine, it is relevant in clinical settings that involve acute or unstable symptom patterns and may assist with maintaining functional stability in these conditions involving episodic or fluctuating manifestations.

The therapeutic domains are relevant in contexts involving heightened systemic burden. Primary uses include Hypertension, Congestive heart failure, and Supportive care for patients with stable coronary artery disease. This therapeutic support is relevant when supportive symptom management is appropriate and helps address symptom clusters that may become intense or disruptive.

The treatment is applied in addressing symptoms related to systemic imbalance and symptoms that create noticeable physiological strain. It contributes to easing the overall symptom load and may help patients cope more steadily during periods of increased physiological stress.

Quick Fact: Relief for Noticeable Physiological Strain

Regulatory References

  1. NPS MedicineWise medicine finder

Eligibility and Restrictions for Use

Official Eligibility and Contraindications

Coversum (perindopril) is an Angiotensin-Converting Enzyme (ACE) inhibitor whose use is governed by a defined set of regulatory eligibility rules and absolute contraindications. These rules strictly determine who may or may not use the medicine.

Classification Eligibility Status as Defined in Official Sources
Contraindicated Populations Patients with a history of angioedema (hereditary, idiopathic, or related to previous ACE inhibitor treatment), hypersensitivity to perindopril or any other ACE inhibitor, pregnant women in their second and third trimesters, and patients on aliskiren therapy who have diabetes or renal impairment (GFR < 60 mL/ min/1.73 m^2). Use is also prohibited if undergoing certain extracorporeal treatments (e.g., specific dialysis/filtration membranes) or within 36 hours of taking sacubitril/valsartan.
Use Not Recommended/Restricted Use is not recommended during the first trimester of pregnancy and while breastfeeding. It is also not recommended for use in children and adolescents under 18 years of age as safety and efficacy have not been established. Patients with severe renal impairment (creatinine clearance < 30 mL/ min) are also restricted.

This eligibility structure relies on absolute exclusions to mitigate the risk of serious adverse events like angioedema and fetal harm. The overall profile restricts the drug’s use based on prior medical history, concurrent drug treatments, specific organ dysfunction (renal), and physiological states (pregnancy/lactation) as explicitly mandated by authoritative regulatory agencies.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Coversum (perindopril) has officially documented interaction patterns primarily concerning electrolyte balance, blood pressure control, and specific prohibitions. Co-administration with Sacubitril/Valsartan is strictly prohibited due to the heightened risk of angioedema. A mandatory 36-hour washout period is required when transitioning between these medicines. Furthermore, the combination with Aliskiren is contraindicated only in patients who have diabetes mellitus or documented moderate-to-severe renal impairment.

Pharmacodynamic and Exposure Interactions

The use with potassium-sparing diuretics (such as spironolactone or amiloride), potassium supplements, or salt substitutes containing potassium carries a high, documented risk of hyperkalemia (elevated serum potassium). Combining Coversum with Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) may diminish the antihypertensive effect and increase the risk of renal function deterioration, particularly in elderly or volume-depleted patients. Co-administration with Lithium is documented to increase serum lithium levels and the potential for toxicity. The regulatory label notes that food may reduce the bioavailability of the active metabolite, Perindoprilat, which is why administration before a meal is advised. Its use is also restricted during certain extracorporeal treatments, such as dialysis using specific high-flux membranes, due to the risk of severe reactions.

Mechanism of Action

Coversum is a pharmaceutical preparation containing perindopril, a prodrug, and L-arginine, a physiological amino acid. Following oral administration, the prodrug perindopril undergoes hepatic hydrolysis to yield its active metabolite, perindoprilat.

Perindoprilat functions as a competitive inhibitor of Angiotensin-Converting Enzyme (ACE), an enzyme primarily located in the vascular endothelium. ACE inhibition prevents the conversion of the inactive decapeptide Angiotensin I to the potent octapeptide vasoconstrictor Angiotensin II within the Renin-Angiotensin-Aldosterone System (RAAS). Reduced Angiotensin II plasma concentration leads to decreased stimulation of the AT1 receptors on vascular smooth muscle cells, decreasing peripheral vasoconstriction.

Simultaneously, ACE inhibition also reduces the enzymatic degradation of the endogenous vasodilator bradykinin, leading to its local accumulation. Bradykinin promotes the release of other vasodilating mediators, including nitric oxide (NO) and prostacyclin, which act on vascular smooth muscle.

The L-arginine component serves as the endogenous substrate for nitric oxide synthase (NOS), supporting the synthesis of nitric oxide, an endothelium-derived relaxing factor. This NO production contributes to vascular smooth muscle relaxation. The combined inhibition of Angiotensin II formation and enhancement of NO/bradykinin-mediated vasodilation results in a system-level physiological consequence of decreased total peripheral resistance and subsequent modulation of systemic vascular tone.

Dosage and Administration Information

How to Use Coversum

Coversum, which contains the active ingredient Perindopril, is an oral tablet intended for long-term management of chronic cardiovascular conditions. The administration principles are designed to ensure consistent systemic exposure and dose titration.

Administration and Timing

Perindopril is administered once daily in the morning, and instructions state the tablet is taken before a meal (on an empty stomach) to optimize its absorption. The dosage is not static but follows a pattern of titration, where treatment begins with a low starting dose and is gradually increased, based on clinical response and tolerance, toward a specified maintenance dose. For instance, the starting dose for hypertension is often 4 mg (Erbumine salt) or 5 mg (Arginine salt) daily, with increases typically occurring after a minimum of two weeks of observation.

Official Dosing Regimens

Dosage limits and initial doses vary by the specific indication and the salt form used. The maximum daily dose for the treatment of hypertension may be up to 10 mg (Arginine salt) or 16 mg (Erbumine salt) per day. In cases of heart failure, the initial dose is lower, starting at 2 mg or 2.5 mg once daily.

Population-Specific Use

Specific adjustments to the initial dose are required for certain patient groups. Older adults (typically defined as ge 65 years) and individuals with impaired kidney function (CrCl < 60 mL/min) are started on a reduced initial dose (e.g., 2 mg or 2.5 mg daily), which is then titrated. Use in the pediatric population is not generally established due to a lack of safety and efficacy data in children. If a daily dose is missed, the protocol is to skip the missed dose and take the next one at the scheduled time; a double dose is not taken to compensate.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Coversum (Perindopril)

Evidence for Use in High Blood Pressure (Essential Hypertension)

Coversum was studied for high blood pressure, with research primarily relying on numerous Randomized Controlled Trials (RCTs). These are studies where participants were randomly assigned to receive either the medicine or a comparison treatment, such as a placebo or another drug, to see how blood pressure measurements were measured to differ. The findings describe patterns observed in these studies related to measured differences in both Systolic and Diastolic Blood Pressure (BP) readings. Large-scale trials also monitored patients over multiple years, with research examining the likelihood of subsequent major vascular events.

However, data show patterns related to a more variable response in some groups, such as individuals with certain low-renin profiles. This suggests that the results apply only to the populations studied, and data for certain groups remain insufficient to fully characterize the blood pressure-lowering effect.

Evidence for Use in Stable Heart Conditions (CAD and Symptomatic CHF)

Coversum was studied for patients with two specific heart conditions: stable coronary artery disease (CAD) and symptomatic chronic heart failure (CHF). The evidence for these uses is derived from separate large-scale clinical research. Studies focusing on stable CAD involved long-term, double-blind trials where researchers monitored the frequency of major events. The primary outcome studies monitored was a composite measure of major cardiac events. Studies reported observed differences in the frequency of specific events, such as non-fatal myocardial infarction, between the groups.

In symptomatic CHF, Coversum was evaluated in RCTs exploring short-term symptom changes and long-term event rates. Studies report how symptoms evolved in the observed populations, and research highlights changes measured in functional assessments. Evidence is limited in some subgroups, especially concerning long-term data for patients with asymptomatic heart failure or heart failure with preserved ejection fraction.

Research Gaps and Areas of Uncertainty

Research highlights what is known — and what is still uncertain. Evidence quality varies across studies, and findings were mixed for some individual outcomes. The key limitations identified include instances where follow-up durations were limited for specific endpoints, and where results apply only to the specific populations and conditions under which they were conducted.

Key Studies & References NICE Guideline NG106: Chronic heart failure in adults: diagnosis and management (ACE inhibitor class guidance)

Frequently Asked Questions (FAQ)

Common questions about Coversum (FAQ)

Q: How quickly does Coversum start to lower blood pressure?

A: Coversum contains the active ingredient perindopril, which is converted to its active form in the body. According to official product information, the active form reaches its highest concentration in the blood within 3 to 7 hours after taking a dose. However, achieving the full blood pressure-lowering effect may take up to a month, based on clinical observations.

Q: What is the benefit of taking Coversum for the heart?

A: Clinical studies have shown an association with a reduced likelihood of cardiovascular death, myocardial infarction, and stroke in patients with stable coronary artery disease. The medicine is also indicated to help improve symptoms in people with chronic heart failure.

Q: Is Coversum the same type of drug as Lisinopril?

A: Coversum (Perindopril) and Lisinopril both belong to the same pharmacological class of medicines, known as Angiotensin-Converting Enzyme (ACE) Inhibitors. This means they share the same primary mechanism of working within the body to lower blood pressure.

Q: What is the difference between Coversum and Ramipril?

A: Both Coversum (Perindopril) and Ramipril are classified as ACE inhibitors, sharing the same basic mechanism for managing blood pressure. They are chemically different compounds. The official product labeling does not provide a direct comparison of effects or safety.

Q: Is it normal to feel a dry cough after starting Coversum?

A: A dry cough is a common side effect of ACE inhibitors like Coversum, as reported in official safety documents. This cough is typically described as persistent and nonproductive. The cough typically resolves upon discontinuation of the medicine.

Q: Does Coversum cause fatigue or dizziness?

A: Official reports list dizziness as a common side effect of Coversum. Fatigue (feeling tired) is also reported in clinical trials, but typically occurs less frequently. These effects are typically noted as more likely following the initial dose or during dose escalation.

Q: Is weight gain a possible side effect of taking Coversum?

A: Weight gain itself is not directly listed as a common or uncommon side effect in official regulatory documents. However, an uncommon reaction reported is edema (generalized swelling). Edema is a fluid-related side effect that can contribute to changes in body weight.

Q: What happens if I drink alcohol while taking Coversum?

A: Official patient information notes that alcohol can increase the medicine’s blood pressure-lowering effect. Combining alcohol with the medicine may increase the risk of dizziness or lightheadedness due to the enhanced blood pressure-lowering effect.

Q: Are there any specific vitamins or supplements that interact with Coversum?

A: Official regulatory warnings note a risk of hyperkalemia (high potassium) with the concurrent use of potassium supplements or potassium-containing salt substitutes. These products are noted for their potential to interact with this medicine.

Q: What is the experience of people taking Coversum long-term?

A: Coversum is indicated for the long-term management of chronic cardiovascular conditions, such as high blood pressure and heart disease. Clinical trials supporting its use have followed patients for multiple years to assess safety and efficacy over extended periods.

Q: What is the half-life of Coversum?

A: The half-life refers to the time it takes for half of the active substance to be cleared from the bloodstream. For the active metabolite of Coversum (perindoprilat), the plasma half-life is approximately 17 hours. This characteristic supports its recommended once-daily dosing.

Q: Can Coversum be used to prevent heart attacks or strokes?

A: Official indications note that Coversum is used to reduce the risk of future cardiovascular events, including stroke and heart attack, in patients with stable coronary artery disease.

Q: What are the signs that Coversum is working effectively?

A: The effectiveness of Coversum is primarily determined by its ability to lower blood pressure. This is monitored through regular blood pressure checks, which help assess the intended systemic effect. The medicine’s effect is also judged by its role in reducing the risk of cardiovascular events over time.

Q: Is Coversum available over the counter?

A: Official regulatory documents and dispensing information confirm that Coversum is a prescription-only medicine. It is not available for purchase over the counter.

Q: Is it normal for my heart rate to change slightly after starting Coversum?

A: Coversum primarily works to regulate blood pressure. While its main action is not directly on heart rate, official reports have noted that tachycardia (an unusually fast heart rate) is an uncommon adverse effect. This suggests that the heart rate may occasionally be affected.

Q: Why do people sometimes call Coversum by a different name?

A: Coversum is a trade name for the medicine used in specific regions. The core active ingredient is called Perindopril. Therefore, healthcare providers or patients may sometimes refer to the medicine by its generic name or other brand names used globally.

Q: Can Coversum affect my ability to drive or operate machinery?

A: Official safety information notes that due to potential side effects like dizziness or fatigue, use of the medicine may impair the ability to drive or operate machinery. Caution is warranted, particularly during the initial phases of treatment.

Q: Are the effects of Coversum reduced over time?

A: Regulatory documents do not note any reduction in the long-term effectiveness (tachyphylaxis) of the medicine. Clinical studies support its continued efficacy for chronic conditions over extended periods.

Q: Why is Coversum sometimes prescribed for people without high blood pressure?

A: Coversum is officially indicated for the treatment of conditions other than just high blood pressure. These indications include the management of stable coronary artery disease (CAD) and the treatment of symptomatic chronic heart failure (CHF).

Q: Why do people experience swelling of the face or lips (angioedema) with Coversum?

A: Angioedema is a known, rare, and serious side effect of ACE inhibitors. Its occurrence is related to the medicine’s mechanism of action, which can lead to sudden swelling of tissues in the face, lips, tongue, or throat.

Q: Do clinical trials show a reduction in mortality with Coversum?

A: Clinical trials conducted in specific patient populations, such as those with stable coronary artery disease, have reported an observed reduction in cardiovascular death.

Q: Is it important to keep track of my blood pressure when on Coversum?

A: Since the medicine is intended to lower blood pressure, official guidance on dose titration and treatment effectiveness relies on blood pressure monitoring. This tracking helps assess the medicine’s intended systemic effect.

Q: What kind of research supports the use of Coversum for heart failure?

A: The evidence for heart failure use is based on Randomized Controlled Trials (RCTs). These studies examined patients with symptomatic chronic heart failure (CHF) and monitored changes in their symptoms, functional status, and long-term event rates.

Q: Is it better to take Coversum in the morning or at night?

A: Official instructions specify that Coversum should be administered once daily in the morning. Official instructions also specify that the tablet should be administered before a meal (on an empty stomach) to optimize the absorption of the active ingredient.

How should Coversum be stored and disposed of?

Storage and Disposal Requirements

Official regulatory documentation requires Coversum (Perindopril/Indapamide) to be stored out of the sight and reach of children.

Requirement Storage Mandate
Container Protection Keep the container tightly closed in the original packaging to protect from moisture.
Temperature/Location Store in a cool and dry place, away from excessive heat and direct sunlight. Certain formulations specify Do not store above 25 C.
Stability Limit Do not use this medicine after the expiry date stated on the container.
Disposal Rule Do not throw away via wastewater or household waste. Ask your pharmacist how to throw away unused medicine to help protect the environment.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Coversum found in:

A-Z Index: